Identification of new p53 target microRNAs by bioinformatics and functional analysis

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Bisio, Alessandra ^a   De Sanctis, Veronica ^a   Del Vescovo, Valerio ^a   Denti, Michela A ^a   Jegga, Anil G ^b   Inga, Alberto ^a   Ciribilli, Yari ^a  

^a UNIVERSITY OF TRENTO   (Italy)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

miRNA; p53 family; Promoter occupancy; Transcription regulation

Indexed keywords

DOXORUBICIN; MICRORNA; MICRORNA 106A; MICRORNA 10B; MICRORNA 1204; MICRORNA 1206; MICRORNA 145; MICRORNA 151A; MICRORNA 191; MICRORNA 198; MICRORNA 202; MICRORNA 221; MICRORNA 23B; MICRORNA 320; MICRORNA 320A; MICRORNA 328; MICRORNA 34A; MICRORNA 455; MICRORNA 671; NUTLIN 3; PHOSPHOPROTEIN; PROTEIN P53; PROTEIN P63BETA; PROTEIN P73BETA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; BIOINFORMATICS; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG EFFECT; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; NONHUMAN; PROMOTER REGION; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANTIBIOTICS, ANTINEOPLASTIC; BINDING SITES; CHROMATIN; COMPUTATIONAL BIOLOGY; DNA-BINDING PROTEINS; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HCT116 CELLS; HUMANS; LUCIFERASES, FIREFLY; MCF-7 CELLS; MICRORNAS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RESPONSE ELEMENTS; RNA, LONG NONCODING; SACCHAROMYCES CEREVISIAE; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84887921212     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-552     Document Type: Article

References (69)

1. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1(1):45-49. 10.1038/ng0492-45, 1301998.
2. Appella E, Anderson CW. Dynamic interactions of proteins in complex networks. FEBS J 2009, 276(19):5380. 10.1111/j.1742-4658.2009.07252.x, 19712105.
3. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored?. Cell Death Differ 2006, 13(6):1027-1036. 10.1038/sj.cdd.4401910, 16557269.
4. Espinosa JM. Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 2008, 27(29):4013-4023. 10.1038/onc.2008.37, 2914794, 18278067.
5. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9(5):402-412. 10.1038/nrm2395, 18431400.
6. Vousden KH. Outcomes of p53 activation-spoilt for choice. J Cell Sci 2006, 119(Pt 24):5015-5020.
7. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126(1):107-120. 10.1016/j.cell.2006.05.036, 16839880.
8. Goldstein I, Rotter V. Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrinol Metab 2012, 23(11):567-575. 10.1016/j.tem.2012.06.007, 22819212.
9. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126(1):121-134. 10.1016/j.cell.2006.05.034, 16839881.
10. Taura M, Eguma A, Suico MA, Shuto T, Koga T, Komatsu K, Komune T, Sato T, Saya H, Li JD, et al. p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol Cell Biol 2008, 28(21):6557-6567. 10.1128/MCB.01202-08, 2573237, 18779317.
11. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, Bergmann A, Johnson RL, Barton MC. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A 2009, 106(28):11612-11616. 10.1073/pnas.0813177106, 2710642, 19556538.
12. Suzuki HI, Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl) 2010, 88(11):1085-1094. 10.1007/s00109-010-0650-1, 20614100.
13. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012, 12(9):613-626. 10.1038/nrc3318, 22898542.
14. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001, 107(7):823-826. 10.1016/S0092-8674(01)00616-X, 11779458.
15. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302(1):1-12. 10.1016/j.ydbio.2006.08.028, 16989803.
16. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447(7148):1130-1134. 10.1038/nature05939, 17554337.
17. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Orntoft TF, Andersen CL, Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008, 68(24):10094-10104. 10.1158/0008-5472.CAN-08-1569, 2836584, 19074875.
18. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 2009, 106(9):3207-3212. 10.1073/pnas.0808042106, 2651330, 19202062.
19. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, Lowenstein CJ. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A 2010, 107(14):6334-6339. 10.1073/pnas.0911082107, 2851979, 20308559.
20. Yamakuchi M, Ferlito M, Lowenstein C. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 2008, 105(36):13421-13426. 10.1073/pnas.0801613105, 2533205, 18755897.
21. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, Zhang LJ, Thorne RF, Wilmott J, Scolyer RA, et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci U S A 2011, 108(38):15840-15845. 10.1073/pnas.1019312108, 3179083, 21896753.
22. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009, 16(1):23-29. 10.1038/nsmb.1533, 19079265.
23. Tian S, Huang S, Wu S, Guo W, Li J, He X. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem Biophys Res Commun 2010, 396(2):435-439. 10.1016/j.bbrc.2010.04.112, 20417621.
24. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009, 23(7):862-876. 10.1101/gad.1767609, 2666337, 19293287.
25. Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ, Feng Z. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 2010, 38(5):689-699. 10.1016/j.molcel.2010.05.027, 2900922, 20542001.
26. Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, Gonzalez S. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 2010, 9(16):3277-3285.
27. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 2010, 16(10):1134-1140. 10.1038/nm.2227, 3019350, 20871609.
28. Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, Ramos KS, Young KH, Li Y. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011, 30(7):843-853. 10.1038/onc.2010.457, 3021102, 20935678.
29. McLure KG, Lee PW. How p53 binds DNA as a tetramer. EMBO J 1998, 17(12):3342-3350. 10.1093/emboj/17.12.3342, 1170672, 9628871.
30. Ma B, Levine AJ. Probing potential binding modes of the p53 tetramer to DNA based on the symmetries encoded in p53 response elements. Nucleic Acids Res 2007, 35(22):7733-7747. 10.1093/nar/gkm890, 2190717, 17986463.
31. Jordan JJ, Menendez D, Inga A, Noureddine M, Bell DA, Resnick MA. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet 2008, 4(6):e1000104. 10.1371/journal.pgen.1000104, 2518093, 18714371.
32. Tokino T, Thiagalingam S, el-Deiry WS, Waldman T, Kinzler KW, Vogelstein B. p53 tagged sites from human genomic DNA. Hum Mol Genet 1994, 3(9):1537-1542. 10.1093/hmg/3.9.1537, 7833908.
33. Veprintsev DB, Fersht AR. Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res 2008, 36(5):1589-1598. 10.1093/nar/gkm1040, 2275157, 18234719.
34. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006, 124(1):207-219. 10.1016/j.cell.2005.10.043, 16413492.
35. Ethayathulla AS, Tse PW, Monti P, Nguyen S, Inga A, Fronza G, Viadiu H. Structure of p73 DNA-binding domain tetramer modulates p73 transactivation. Proc Natl Acad Sci U S A 2012, 109(16):6066-6071. 10.1073/pnas.1115463109, 3341074, 22474346.
36. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009, 9(10):724-737. 10.1038/nrc2730, 19776742.
37. Jegga AG, Inga A, Menendez D, Aronow BJ, Resnick MA. Functional evolution of the p53 regulatory network through its target response elements. Proc Natl Acad Sci U S A 2008, 105(3):944-949. 10.1073/pnas.0704694105, 2242714, 18187580.
38. Sinha AU, Kaimal V, Chen J, Jegga AG. Dissecting microregulation of a master regulatory network. BMC Genomics 2008, 9:88. 10.1186/1471-2164-9-88, 2289817, 18294391.
39. Gowrisankar S, Jegga AG. Regression based predictor for p53 transactivation. BMC Bioinforma 2009, 10:215.
40. Storici F, Resnick MA. The delitto perfetto approach to in vivo site-directed mutagenesis and chromosome rearrangements with synthetic oligonucleotides in yeast. Methods Enzymol 2006, 409:329-345.
41. Tomso DJ, Inga A, Menendez D, Pittman GS, Campbell MR, Storici F, Bell DA, Resnick MA. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci USA 2005, 102(18):6431-6436. 10.1073/pnas.0501721102, 1088378, 15843459.
42. Monti P, Perfumo C, Bisio A, Ciribilli Y, Menichini P, Russo D, Umbach DM, Resnick MA, Inga A, Fronza G. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. Mol Cancer Res 2011, 9(3):271-279. 10.1158/1541-7786.MCR-10-0496, 3077904, 21343334.
43. Andreotti V, Ciribilli Y, Monti P, Bisio A, Lion M, Jordan J, Fronza G, Menichini P, Resnick MA, Inga A. p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system. PLoS One 2011, 6(6):e20643. 10.1371/journal.pone.0020643, 3107237, 21674059.
44. Barbareschi M, Cantaloni C, Del Vescovo V, Cavazza A, Monica V, Carella R, Rossi G, Morelli L, Cucino A, Silvestri M, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol 2011, 136(5):773-782. 10.1309/AJCPYY79XAGRAYCJ, 22031317.
45. Ciribilli Y, Monti P, Bisio A, Nguyen HT, Ethayathulla AS, Ramos A, Foggetti G, Menichini P, Menendez D, Resnick MA, et al. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code. Nucleic Acids Res 2013, 41(18):8637-8653. 10.1093/nar/gkt657, 3794606, 23892287.
46. Viiri J, Amadio M, Marchesi N, Hyttinen JM, Kivinen N, Sironen R, Rilla K, Akhtar S, Provenzani A, D'Agostino VG, et al. Autophagy activation clears ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human retinal pigment epithelial cells. PLoS One 2013, 8(7):e69563. 10.1371/journal.pone.0069563, 3726683, 23922739.
47. Ciribilli Y, Andreotti V, Menendez D, Langen JS, Schoenfelder G, Resnick MA, Inga A. The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound. PLoS One 2010, 5(4):e10236. 10.1371/journal.pone.0010236, 2858160, 20422012.
48. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26(5):745-752. 10.1016/j.molcel.2007.05.010, 1939978, 17540599.
49. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007, 26(5):731-743. 10.1016/j.molcel.2007.05.017, 17540598.
50. Monti P, Ciribilli Y, Jordan J, Menichini P, Umbach DM, Resnick MA, Luzzatto L, Inga A, Fronza G. Transcriptional functionality of germ line p53 mutants influences cancer phenotype. Clin Cancer Res 2007, 13(13):3789-3795. 10.1158/1078-0432.CCR-06-2545, 2128783, 17606709.
51. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995, 270(37):21429-21432. 10.1074/jbc.270.37.21429, 7665550.
52. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74(6):957-967. 10.1016/0092-8674(93)90719-7, 8402885.
53. Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-Dependent induction of PVT1 and miR-1204. J Biol Chem 2012, 287(4):2509-2519. 10.1074/jbc.M111.322875, 3268411, 22110125.
54. Au Yeung CL, Tsang TY, Yau PL, Kwok TT. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 2011, 30(21):2401-2410. 10.1038/onc.2010.613, 21242962.
55. Ding J, Huang S, Wu S, Zhao Y, Liang L, Yan M, Ge C, Yao J, Chen T, Wan D, et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol 2010, 12(4):390-399. 10.1038/ncb2039, 20305651.
56. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007, 67(23):11099-11101. 10.1158/0008-5472.CAN-07-2672, 18056431.
57. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137(3):413-431. 10.1016/j.cell.2009.04.037, 19410540.
58. Perez CA, Ott J, Mays DJ, Pietenpol JA. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene 2007, 26(52):7363-7370. 10.1038/sj.onc.1210561, 17563751.
59. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416(6880):560-564. 10.1038/416560a, 11932750.
60. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010, 17(6):901-911. 10.1038/cdd.2010.35, 20379196.
61. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2011, 2(12):1203-1217. 3282078, 22203497.
62. Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J, Ligon KL, Kesari S, Esau C, Stephens RM, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res 2011, 71(10):3563-3572. 10.1158/0008-5472.CAN-10-3568, 3096675, 21471404.
63. Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, Liu Z. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem 2010, 285(11):7986-7994. 10.1074/jbc.M109.062877, 2832949, 20075075.
64. Jin L, Wessely O, Marcusson E, Ivan C, Calin G, Alahari SK. Pro-oncogenic factors miR-23b- and miR-27b are regulated by Her2/Neu, EGF, and TNFalpha in breast cancer. Cancer Res 2013, 280(16):16030-16037.
65. Li X, Xu F, Chang C, Byon J, Papayannopoulou T, Deeg HJ, Marcondes AM. Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica 2013, 98(3):414-419. 10.3324/haematol.2012.071753, 3659943, 22983574.
66. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449(7163):682-688. 10.1038/nature06174, 17898713.
67. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005, 7(11):1074-1082. 10.1038/ncb1314, 16244670.
68. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, et al. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med 2012, 4(11):1214-1229. 10.1002/emmm.201201483, 3494877, 23125021.
69. Hu R, O'Connell RM. MiR-23b is a safeguard against autoimmunity. Nat Med 2012, 18(7):1009-1010. 10.1038/nm.2849, 22772548.